A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors
Phase of Trial: Phase I/II
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs Ganetespib (Primary) ; Sirolimus
- Indications Nerve sheath neoplasms
- Focus Adverse reactions
- 16 Jul 2018 Status changed from active, no longer recruiting to completed.
- 09 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
- 09 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Apr 2018.